DYRK1A overexpression decreases plasma lecithin:cholesterol acyltransferase activity and apolipoprotein A-I levels. 2013

Asma Tlili, and Christophe Noll, and Sandrine Middendorp, and Arnaud Duchon, and Marie Jouan, and Eva Benabou, and Yann Hérault, and Jean-Louis Paul, and Jean-Maurice Delabar, and Nathalie Janel
Université Paris Diderot, Sorbonne Paris Cité, Unit of Functional and Adaptive Biology (BFA), EAC-CNRS 4413, Case 7104, 75205 Paris cedex 13, France.

OBJECTIVE Down syndrome is caused by trisomy of all or part of human chromosome 21. Individuals with Down syndrome present some metabolic abnormalities involving lipoproteins, notably lower high-density lipoprotein levels associated with altered lecithin:cholesterol acyltransferase activity and apolipoprotein A-I levels. DYRK1A is a kinase overexpressed in Down syndrome that can activate the STAT3 pathway, which is involved in lecithin:cholesterol acyltransferase expression. Therefore, we characterized the role of DYRK1A overexpression on lecithin:cholesterol acyltransferase activity and expression in mouse models. METHODS Effects of Dyrk1a overexpression were examined in mice overexpressing Dyrk1a by ELISA, chemical analyses and Western blotting. RESULTS Overexpression of DYRK1A decreased plasma lecithin:cholesterol acyltransferase activity and hepatic STAT3 activation, which was associated with activation of SHP2, a tyrosine phosphatase. Although hepatic apolipoprotein E and D levels were increased in mice overexpressing DYRK1A, decreased plasma lecithin:cholesterol acyltransferase activity was associated with decreased hepatic and plasma apolipoprotein A-I levels. High-density lipoprotein-cholesterol levels were also decreased in plasma despite similar total cholesterol and non-high-density lipoprotein-cholesterol levels. CONCLUSIONS We identified the role of DYRK1A overexpression on altered lipoprotein metabolism.

UI MeSH Term Description Entries
D007862 Phosphatidylcholine-Sterol O-Acyltransferase An enzyme secreted from the liver into the plasma of many mammalian species. It catalyzes the esterification of the hydroxyl group of lipoprotein cholesterol by the transfer of a fatty acid from the C-2 position of lecithin. In familial lecithin:cholesterol acyltransferase deficiency disease, the absence of the enzyme results in an excess of unesterified cholesterol in plasma. Lecithin Cholesterol Acyltransferase,Cholesterol Ester Lysolecithin Acyltransferase,Lecithin Acyltransferase,Phosophatidylcholine-Sterol Acyltransferase,Acyltransferase, Lecithin,Acyltransferase, Lecithin Cholesterol,Acyltransferase, Phosophatidylcholine-Sterol,Cholesterol Acyltransferase, Lecithin,O-Acyltransferase, Phosphatidylcholine-Sterol,Phosophatidylcholine Sterol Acyltransferase,Phosphatidylcholine Sterol O Acyltransferase
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008297 Male Males
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D000097603 Dyrk Kinases PROTEIN KINASES that can phosphorylate aromatic amino acid residue TYROSINE as well as aliphatic amino acid residues SERINE and THREONINE. Dual Specificity Protein Kinase Dyrk,Dual Specificity Tyrosine-Phosphorylation Regulated Kinase 1A,Dual Specificity Tyrosine-Phosphorylation Regulated Kinase 1B,Dual Specificity Tyrosine-Phosphorylation Regulated Kinase 2,Dual Specificity Tyrosine-Phosphorylation Regulated Kinase 3,Dual Specificity Tyrosine-Phosphorylation Regulated Kinase 4,Dual Specificity Tyrosine-Phosphorylation Regulated Kinases,Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 4A,Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 4B,DYRK4A protein,DYRK4B protein,Kinases, Dyrk
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001057 Apolipoproteins E A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III. Apo-E,Apo E,Apo E Isoproteins,ApoE,Apolipoprotein E Isoproteins,Apoprotein (E),Apoproteins E,Isoproteins, Apo E,Isoproteins, Apolipoprotein E

Related Publications

Asma Tlili, and Christophe Noll, and Sandrine Middendorp, and Arnaud Duchon, and Marie Jouan, and Eva Benabou, and Yann Hérault, and Jean-Louis Paul, and Jean-Maurice Delabar, and Nathalie Janel
June 2013, Molecular and cellular biochemistry,
Asma Tlili, and Christophe Noll, and Sandrine Middendorp, and Arnaud Duchon, and Marie Jouan, and Eva Benabou, and Yann Hérault, and Jean-Louis Paul, and Jean-Maurice Delabar, and Nathalie Janel
February 2018, Journal of lipid research,
Asma Tlili, and Christophe Noll, and Sandrine Middendorp, and Arnaud Duchon, and Marie Jouan, and Eva Benabou, and Yann Hérault, and Jean-Louis Paul, and Jean-Maurice Delabar, and Nathalie Janel
February 1995, Journal of lipid research,
Asma Tlili, and Christophe Noll, and Sandrine Middendorp, and Arnaud Duchon, and Marie Jouan, and Eva Benabou, and Yann Hérault, and Jean-Louis Paul, and Jean-Maurice Delabar, and Nathalie Janel
March 1986, European journal of biochemistry,
Asma Tlili, and Christophe Noll, and Sandrine Middendorp, and Arnaud Duchon, and Marie Jouan, and Eva Benabou, and Yann Hérault, and Jean-Louis Paul, and Jean-Maurice Delabar, and Nathalie Janel
April 1993, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies,
Asma Tlili, and Christophe Noll, and Sandrine Middendorp, and Arnaud Duchon, and Marie Jouan, and Eva Benabou, and Yann Hérault, and Jean-Louis Paul, and Jean-Maurice Delabar, and Nathalie Janel
December 2009, Biochemistry,
Asma Tlili, and Christophe Noll, and Sandrine Middendorp, and Arnaud Duchon, and Marie Jouan, and Eva Benabou, and Yann Hérault, and Jean-Louis Paul, and Jean-Maurice Delabar, and Nathalie Janel
February 2003, Biochimica et biophysica acta,
Asma Tlili, and Christophe Noll, and Sandrine Middendorp, and Arnaud Duchon, and Marie Jouan, and Eva Benabou, and Yann Hérault, and Jean-Louis Paul, and Jean-Maurice Delabar, and Nathalie Janel
January 1978, Scandinavian journal of clinical and laboratory investigation. Supplementum,
Asma Tlili, and Christophe Noll, and Sandrine Middendorp, and Arnaud Duchon, and Marie Jouan, and Eva Benabou, and Yann Hérault, and Jean-Louis Paul, and Jean-Maurice Delabar, and Nathalie Janel
July 2002, Atherosclerosis,
Asma Tlili, and Christophe Noll, and Sandrine Middendorp, and Arnaud Duchon, and Marie Jouan, and Eva Benabou, and Yann Hérault, and Jean-Louis Paul, and Jean-Maurice Delabar, and Nathalie Janel
September 2010, Clinical chemistry and laboratory medicine,
Copied contents to your clipboard!